• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

  1. All
  2. 3rd Party
  1. Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

    Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

  2. Dodge & Cox Balanced Fund Isn't for Everyone

    This Gold-rated fund is not a safe choice, but it's a strong one for the right kind of investor.

  3. Investing in Hidden Assets

    Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.

©2017 Morningstar Advisor. All right reserved.